Literature DB >> 12589660

Alterations and reversibility in the chromatin, cytoskeleton and development of pig oocytes treated with roscovitine.

Jyh-Cherng Ju1, Chih Tsay, Chi-Wai Ruan.   

Abstract

Germinal vesicle (GV) breakdown in mammalian oocytes is regulated by the activation of maturation promoting factor (MPF). We investigated a specific cdc2 kinase inhibitor, roscovitine, to maintain pig oocytes in the GV stage. Cumulus-oocyte complexes (COCs) were aspirated from slaughterhouse ovaries and cultured for 44 hr in NCSU#23 medium containing different levels of roscovitine (0, 10, 20, 30, 40, 50 microM in Experiment 1 and 0, 40, 60, 80, 100, 120 microM in Experiment 2). The COCs were cultured for another 44 hr after removal of the chemical. Twenty oocytes in each group were fixed at 44 hr for immunocytochemical labeling of the cytoskeleton and the rest (approximately 20/group) were fixed at the end of 88 hr after culture. Results showed that the inhibition of the oocyte in the GV stage was not effective when 10-50 microM (Experiment 1) of roscovitine were used (19-34%). When oocytes were released from the inhibitor, similar proportions (70-83%) of oocytes were observed in the MII or advanced stages among treatments. However, when higher concentrations of roscovitine were used (Experiment 2), significantly greater inhibitory effect was observed at the levels of 80-120 microM with 83-91% oocytes being blocked in the GV stage when compared to the control (9%) and the 40-60 microM (27-43%) groups (P < 0.05). Although 15-21% of the oocytes showed abnormal MII morphology with aberrant meiotic spindles and/or formation of cytoplasmic microtubules, a substantial number of oocytes resumed meiosis and reached MII stage at 44 hr after removal of this chemical. In Experiment 3, different concentrations of roscovitine (0, 20, 40, and 80 microM) were tested to examine the length of intervals (0, 11, 22, 33, and 44 hr) for an effective inhibition. Results showed that the inhibitory effect was significantly more prominent at 22 hr than that at 33 and 44 hr after roscovitine treatment in all treatment groups (P < 0.05). This study demonstrated that roscovitine-treated oocytes resumed meiosis after removal of the inhibitor. This could provide flexibility for studying porcine oocyte development and embryo cloning and may have application in other species. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12589660     DOI: 10.1002/mrd.10234

Source DB:  PubMed          Journal:  Mol Reprod Dev        ISSN: 1040-452X            Impact factor:   2.609


  5 in total

1.  Microtubule distribution in somatic cell nuclear transfer bovine embryos following control of nuclear remodeling type.

Authors:  Dae Jin Kwon; Yu Mi Lee; In Sun Hwang; Choon Keun Park; Boo Keun Yang; Hee Tae Cheong
Journal:  J Vet Sci       Date:  2010-06       Impact factor: 1.672

2.  The relationship between apoptosis, chromatin configuration, histone modification and competence of oocytes: A study using the mouse ovary-holding stress model.

Authors:  Juan Lin; Fei Chen; Ming-Ju Sun; Jiang Zhu; You-Wei Li; Liu-Zhu Pan; Jie Zhang; Jing-He Tan
Journal:  Sci Rep       Date:  2016-06-20       Impact factor: 4.379

3.  Effect of roscovitine on developmental competence of small follicle-derived buffalo oocytes.

Authors:  Sriti Pandey; Anjali Somal; Mehtab S Parmar; Swati Gupta; Mukesh K Bharti; Irfan A Bhat; B Indu; Vikash Chandra; G Sai Kumar; G Taru Sharma
Journal:  Indian J Med Res       Date:  2018-12       Impact factor: 2.375

4.  Ascorbic acid improves the developmental competence of porcine oocytes after parthenogenetic activation and somatic cell nuclear transplantation.

Authors:  Michel Kere; Chawalit Siriboon; Neng-Wen Lo; Ngoc Tan Nguyen; Jyh-Cherng Ju
Journal:  J Reprod Dev       Date:  2012-11-15       Impact factor: 2.214

5.  Expression and activation of mitogen-activated protein kinases in matured porcine oocytes under thermal stress.

Authors:  Shih-Ying Yen; Jung-Kai Tseng; Show-Mei Chuang; Shuen-Ei Chen; Jyh-Cherng Ju
Journal:  J Reprod Dev       Date:  2014-08-04       Impact factor: 2.214

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.